Abstract 285P
Background
Adjuvant ET reduces breast cancer recurrence and increases overall survival among patients with early-stage ER+ breast cancer, however a suboptimal number of patients older than 65 years are included in the studies. This study aims to evaluate adherence to adjuvant ET and sexual dysfunction in women >65 years old with early breast cancer.
Methods
Women with a history of early-stage ER+ invasive carcinoma of the breast on adjuvant ET for at least 6 months were invited to participate. Adherence was assessed with Morisky Medication Adherence Scale (MMAS-8). Quality of life was assessed using EORTC QLQ C30 and BR-23 forms. Sexuality was assessed with the Female Sex Function Index questionnaire. Patients were stratified according to age <=65 years and > 65 years old. Qualitative variables were compared between groups using the Chi-square or exact Chi-square test and for quantitative variables the non-parametric Mann-Whitney test was used.
Results
From June 2021 to March 2024, 774 women from 15 Brazilian institutions were recruited. Mean age was 62 y.o, mean tumor size was 2.24 cm, mean duration of ET was 3.2y. About 191 patients (24.7%) were older than 65y, 69.6% of them were high adherent to ET and 70.7% had sexual dysfunction. In comparison with women <=65 y.o, older women were associated with private healthcare insurance (p=0.003), living with no partner (p < 0.0001), prior lumpectomy (p = 0.0017), prior sentinel node biopsy (p = 0.03), no prior chemotherapy (p < 0.0001), use of aromatase inhibitors (p < 0.0001) and use of concomitant medications (p < 0,0001). Patients older than 65 years were more associated with lower adherence (p = 0.0009), but there was no difference in sexual dysfunction in comparison with patients less than 65 y. Patients over 65 years had significantly higher scores for Emotional Functioning, Cognitive Functioning, Social Functioning, Body Image and Future Perspective domains of quality of life.
Conclusions
Patients older than 65 y.o had less aggressive treatments, many better domains in quality of life, but lower adherence to ET than patients aged up to 65 years. An important issue for womens’ health is sexual health and in this context, sexual dysfunction affects women besides age group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - Relationship between initial tumor burden and the probability of pathological complete response within molecular subtypes of early breast cancer treated with neoadjuvant chemotherapy
Presenter: Nicolas Roussot
Session: Poster session 14
260P - Impact of HER2-low status on clinicopathological characteristics and pathological complete response in luminal and triple-negative early breast cancer
Presenter: Katarzyna Pogoda
Session: Poster session 14
261P - Subtyping of residual disease (RD) following neoadjuvant chemotherapy (NACT) for triple negative breast cancer (TNBC): Evolution and prognostic impact
Presenter: Isabel Echavarria Diaz-Guardamino
Session: Poster session 14
262P - Predictive clinico-biological factors of toxicity associated to neo-adjuvant chemo- immunotherapy in early-stage triple-negative breast cancer
Presenter: Elsa Volant
Session: Poster session 14
263P - Association between clinicopathological characteristics and pathological complete response in patients with triple negative breast cancer treated by neoadjuvant chemo-immunotherapy
Presenter: Clara Helal
Session: Poster session 14
264P - Neuropsychological and morphological effects of simultaneous exercise during neo-/adjuvant chemotherapy in breast cancer patients: The Exercise Cancer and Cognition (ECCO) study
Presenter: David Kiesl
Session: Poster session 14
265P - Association of clinical benefit of adjuvant capecitabine and RCB class in triple negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy
Presenter: Shinyoung Lee
Session: Poster session 14
266P - Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): Post-hoc analysis of the GeparOla trial
Presenter: Guillermo Villacampa
Session: Poster session 14
267P - The tumour microenvironment influences long-term tamoxifen treatment response in breast cancer patients
Presenter: Paula Camargo Romera
Session: Poster session 14
268P - Impact of B cell and plasma cell infiltration on survival in early-stage breast cancer (BC) without recurrence
Presenter: Laura Angelats
Session: Poster session 14